CALIWAY BIOPHARMACEUTICALS CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Caliway’s pipeline includes: CBL‑514, an injectable drug targeting localized fat reduction, cellulite, and Dercum’s disease through adipocyte apoptosis; CBA‑539, a long‑acting injectable for hyperpigmentation and skin aging; and CBF‑520, a chemical entity
The content above was translated by Ai
Founded Year
2012
Unified Business No.
53942917
Status
Active
Number of Employees
0
Total Paid-in
Capital
778,600,430 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2025)、Listing(2024)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Caliway Biopharmaceuticals Co., Ltd. is a clinical‑stage biotech company headquartered in New Taipei City, Taiwan, dedicated to discovering novel small‑molecule therapeutics. The company focuses on aesthetic medicine and chronic inflammatory diseases, aiming to provide new, effective treatment options where current therapies are limited.
The content above was translated by Ai
